Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 16/20 | 0.40 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.40 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.40 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.36 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.36 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.36 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4875277 | 1.00 | NOTUM (0.43) | NOTUMMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4910404 | 0.85 | NOTUM (0.48) | NOTUMMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4876132 | 0.83 | KCNJ5 (0.38) | NOTUMMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4876141 | 0.83 | KCNJ5 (0.38) | NOTUMMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4873127 | 0.79 | MAPK14 (0.41) | NOTUMMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4873135 | 0.79 | MAPK14 (0.41) | NOTUMMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4877829 | 0.78 | HSD11B1 (0.37) | MAPK14MAPK13MAPK12MAPK11KDM4E | |
| SCHEMBL4877832 | 0.78 | HSD11B1 (0.37) | MAPK14MAPK13MAPK12MAPK11KDM4E | |
| SCHEMBL4873887 | 0.75 | P2RX7 (0.35) | NOTUMMAPK14KDM4EPOLB | |
| SCHEMBL4873882 | 0.75 | P2RX7 (0.35) | NOTUMMAPK14KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080081825-A1 | Nitrogen-Containing Heterocyclic Compounds and Medicinal Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-04-03 | — | — | US | disclosed |
| EP-1741702-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081825-A1 | Nitrogen-Containing Heterocyclic Compounds and Medicinal Use Thereof | MAPK1, NOS1, NOS2 | NOTUM 1662/4885MAPK14 13/4885MAPK13 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.